title: Efficacy and safety of nab-paclitaxel combined with carboplatin in Chinese patients with melanoma.
abstract: This study aimed to evaluate the efficacy and safety of nab-paclitaxel combined with carboplatin in Chinese patients with melanoma. The treatment regimen consisted of nab-paclitaxel (100 mg/m(2)) and carboplatin (area under the curve = 2) administered on days 1 and 8 every 21 days. All of the patients were evaluated on the basis of efficacy and safety in a two-cycle interval. Of the 45 patients, 18 were chemotherapy naive and 27 were chemotherapy treated. Of these cases, 18 manifested acral melanoma and 27 showed non-acral melanomas. Although chemotherapy-naive patients exhibited a higher response to the treatment, similar progression-free survival (PFS) and overall survival (OS) were detected in chemotherapy-naive and chemotherapy-treated patients. A higher response was observed in non-acral melanomas; however, similar PFS and OS occurred between acral and non-acral melanomas. The most common side effects were alopecia, myelosuppression, and gastrointestinal reaction. Nab-paclitaxel combined with carboplatin is a well-tolerated and effective regimen to treat Chinese patients with melanoma, including acral and non-acral melanomas. This treatment may be an alternative approach for Chinese patients with melanoma, especially those without the opportunity to undergo therapy with immune checkpoint inhibitors.
authors: Biotherapy Center, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, 510060, Guangdong, People's Republic of China.
authors: Yi-qun
authors: YQ
authors: Guo
authors: Ya
authors: Y
authors: Ding
authors: Dan-dan
authors: DD
authors: Li
authors: Jing-jing
authors: JJ
authors: Li
authors: Rui-qing
authors: RQ
authors: Peng
authors: Xi-zhi
authors: XZ
authors: Wen
authors: Xing
authors: X
authors: Zhang
authors: Xiao-Shi
authors: XS
authors: Zhang
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000418:Albumins / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002681:China; D005260:Female; D006801:Humans; D008297:Male; D008545:Melanoma / Q000188:drug therapy* / Q000401:mortality; D008875:Middle Aged; D017239:Paclitaxel / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000401:mortality; D055815:Young Adult
chemical_list: C520255:130-nm albumin-bound paclitaxel; D000418:Albumins; D000970:Antineoplastic Agents; D016190:Carboplatin; D017239:Paclitaxel